Publications

Li Y, Flavell RR, Juarez R, Chow M, Wu C, Tsai K, Daud A, Behr SC. Retrospective study of the incidence of sarcoidosis-like reaction in patients treated with immunotherapy. Clinical radiology. 2022. PMID: 36344282

Thomas A, Fontaine SD, Diolaiti ME, Desai P, Kumar R, Takahashi N, Sciuto L, Nichols S, Ashworth A, Feng FY, Ashley GW, Nguyen M, Pommier Y, Santi DV. PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors. Molecular cancer therapeutics. 2022. PMID: 35999657

Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, Ibrahim T, Byers LA, Sasano H, Umejiego J, Pavel M. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. The oncologist. 2022. PMID: 35983951

Rugo HS, Umanzor GA, Kwan MR, Cutler DL. Reply to Z.R. McCaw et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022. PMID: 36346667

Huppert LA, Walker Z, Li M, Kim MO, Callan J, Brandman D, Majure M, Melisko ME, Rugo HS, Behr S, Chien AJ. Clinical characteristics and outcomes in patients with metastatic breast cancer and pseudocirrhosis: a single center retrospective cohort study. Breast cancer research and treatment. 2022. PMID: 36319907

Rugo HS, Raskina K, Schrock AB, Madison RW, Graf RP, Sokol ES, Sivakumar SS, Lee JK, Fisher V, Oxnard GR, Tukachinsky H. Biology and targetability of the extended spectrum of PIK3CA mutations (PIK3CAm) detected in breast carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022. PMID: 36321996

Cheng ML, Lee JK, Kumar R, Klein H, Raskina K, Schrock AB, Michael KS, Mazor T, Cerami E, Oxnard GR, Liu D, Beltran H, Sholl LM, Nishino M, J?nne PA. Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non-Small-Cell Lung Cancer. JCO precision oncology. 2022. PMID: 36455195

Tempero M. Welcome Aboard! Journal of the National Comprehensive Cancer Network : JNCCN. 2022. PMID: 36351337

Saliba AN, Kaufmann SH, Stein EM, Patel PA, Baer MR, Stock W, Deininger MW, Blum W, Schiller GJ, Olin RL, Litzow MR, Lin TL, Ball BJ, Boyiadzis M, Traer E, Odenike O, Arellano ML, Walker AR, Duong VH, Kovacsovics TJ, Collins RH, Shoben AB, Heerema NA, Foster MC, Peterson KL, Schneider PA, Martycz M, Gana T, Rosenberg L, Marcus S, Yocum AO, Chen TL, Stefanos M, Mims AS, Borate U, Burd A, Druker BJ, Levine RL, Byrd JC, Foran JM. Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. Blood advances. 2022. PMID: 36315007

Naing A, Algazi AP, Falchook GS, Creelan BC, Powderly J, Rosen S, Barve M, Mettu NB, Triozzi PL, Hamm J, Zhou G, Walker C, Dong Z, Patel MR. Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors. Cancer. 2022. PMID: 36309837

Logan AC. Measurable residual disease in acute lymphoblastic leukemia: How low is low enough? Best practice & research. Clinical haematology. 2022. PMID: 36517126

Benjamin DJ, Chen S, Eldredge JB, Schokrpur S, Li D, Quan Z, Chan JW, Cummings AL, Daly ME, Goldman JW, Gubens MA, Harris JP, Onaitis MW, Zhu VW, Patel SP, Kelly K. The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study. JTO clinical and research reports. 2022. PMID: 36426286

Kemeny MM, Zhao F, Forastiere AA, Catalano P, Hamilton SR, Miedema BW, Dawson NA, Weiner LM, Smith BD, Mason BA, Graziano SL, Gilman PB, Venook AP, Pinto HA, Whitehead RP, O'Dwyer PJ, Benson AB. Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292). Annals of surgical oncology. 2022. PMID: 36305992

MacKenzie TC, Schwab ME, Lianoglou BR, Gano D, Gonzalez J, Arvon RL, Baschat AA, Bianchi DW, Bitanga M, Bourguignon A, Brown RN, Chen B, Chien M, Davis-Nelson S, de Laat MWM, Ekwattanakit S, Gollin Y, Hirata G, Jelin A, Jolley J, Meyer P, Miller J, Norton ME, Ogasawara KK, Panchalee T, Schindewolf E, Shaw SW, Stumbaugh TL, Thompson AA, Towner D, Tsai PS, Viprakasit V, Volanakis E, Vichinsky E, Allen IE, Zhang L. The impact of in utero transfusions on perinatal outcomes in patients with alpha thalassemia major: the UCSF registry. Blood advances. 2022. PMID: 36306387

Ragavan MV, Legaspi N, LaLanne A, Hong JC, Small EJ, Borno HT. Analysis of Serious Adverse Event Reporting for Patients Enrolled in Cancer Clinical Trials During the COVID-19 Pandemic. JAMA oncology. 2022. PMID: 36301577

Mo SS, Cleveland J, Rubenstein JL. Primary CNS lymphoma: update on molecular pathogenesis and therapy. Leukemia & lymphoma. 2022. PMID: 36286546

Zaman A, Bivona TG. Quantitative Framework for Bench-to-Bedside Cancer Research. Cancers. 2022. PMID: 36358671

McNamara MG, Bridgewater J, Goyal L, Jacobs T, Wagner AD, Goldstein D, Shroff R, Moehler M, Lowery M, Bekaii-Saab T, Kelley RK, Furuse J, Rimassa L, Morizane C, Lamarca A, Hubner R, Knox J, Valle J. What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literature. BMJ open. 2022. PMID: 36288834

O'Leary PC, Chen H, Doruk YU, Williamson T, Polacco B, McNeal AS, Shenoy T, Kale N, Carnevale J, Stevenson E, Quigley DA, Chou J, Feng FY, Swaney DL, Krogan NJ, Kim M, Diolaiti ME, Ashworth A. Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2. Cancer research. 2022. PMID: 36273492

Ashley E. Rosko, Carolyn J. Presley, Grant R. Williams, Rebecca L. Olin. Cancer and Aging. . 2022. PMID: